Jared Baeten

Summary

Publications

  1. pmc Preexposure prophylaxis for HIV prevention: where have we been and where are we going?
    Jared M Baeten
    Department of Global Health, University of Washington, Seattle, WA 98104, USA
    J Acquir Immune Defic Syndr 63:S122-9. 2013
  2. pmc Use of antiretrovirals for HIV prevention: what do we know and what don't we know?
    Jared M Baeten
    Department of Global Health, University of Washington, Seattle, WA 98104, USA
    Curr HIV/AIDS Rep 10:142-51. 2013
  3. pmc Oral antiretroviral chemoprophylaxis: current status
    Jared Baeten
    Department of Global Health, University of Washington, Seattle, Washington, USA
    Curr Opin HIV AIDS 7:514-9. 2012
  4. pmc Systemic and topical drugs for the prevention of HIV infection: antiretroviral pre-exposure prophylaxis
    Jared Baeten
    Department of Global Health, University of Washington, USA
    Annu Rev Med 64:219-32. 2013
  5. pmc Clinical and virologic response to episodic acyclovir for genital ulcers among HIV-1 seronegative, herpes simplex virus type 2 seropositive African women: a randomized, placebo-controlled trial
    Jared M Baeten
    Department of Global Health, University of Washington, Seattle, WA 98104, USA
    Sex Transm Dis 39:21-4. 2012
  6. pmc Antiretroviral prophylaxis for HIV prevention in heterosexual men and women
    Jared M Baeten
    Department of Global Health, University of Washington, Seattle, WA 98104, USA
    N Engl J Med 367:399-410. 2012
  7. doi request reprint A prospective study of contraceptive use among African women in HIV-1 serodiscordant partnerships
    Renee Heffron
    Department of Epidemiology, University of Washington, Seattle, WA 98104, USA
    Sex Transm Dis 37:621-8. 2010
  8. pmc Male circumcision and risk of male-to-female HIV-1 transmission: a multinational prospective study in African HIV-1-serodiscordant couples
    Jared M Baeten
    University of Washington, WA, USA
    AIDS 24:737-44. 2010
  9. pmc Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study
    Jairam R Lingappa
    Department of Global Health, University of Washington, Seattle, Washington, United States of America
    PLoS ONE 4:e5272. 2009

Collaborators

Detail Information

Publications9

  1. pmc Preexposure prophylaxis for HIV prevention: where have we been and where are we going?
    Jared M Baeten
    Department of Global Health, University of Washington, Seattle, WA 98104, USA
    J Acquir Immune Defic Syndr 63:S122-9. 2013
    ..At this important transition point-from demonstration of efficacy in clinical trials to thinking about implementation and effectiveness-this review addresses where we have been and where we are going with PrEP for HIV prevention...
  2. pmc Use of antiretrovirals for HIV prevention: what do we know and what don't we know?
    Jared M Baeten
    Department of Global Health, University of Washington, Seattle, WA 98104, USA
    Curr HIV/AIDS Rep 10:142-51. 2013
    ....
  3. pmc Oral antiretroviral chemoprophylaxis: current status
    Jared Baeten
    Department of Global Health, University of Washington, Seattle, Washington, USA
    Curr Opin HIV AIDS 7:514-9. 2012
    ..Preexposure prophylaxis (PrEP), in which HIV uninfected persons with ongoing HIV risk use oral antiretroviral medications as chemoprophylaxis against sexual HIV acquisition, is a promising new HIV prevention strategy...
  4. pmc Systemic and topical drugs for the prevention of HIV infection: antiretroviral pre-exposure prophylaxis
    Jared Baeten
    Department of Global Health, University of Washington, USA
    Annu Rev Med 64:219-32. 2013
    ..Next steps in the field include rigorous evaluation of uptake and adherence to PrEP in implementation settings and research into next-generation PrEP agents with longer half-life and less user dependence...
  5. pmc Clinical and virologic response to episodic acyclovir for genital ulcers among HIV-1 seronegative, herpes simplex virus type 2 seropositive African women: a randomized, placebo-controlled trial
    Jared M Baeten
    Department of Global Health, University of Washington, Seattle, WA 98104, USA
    Sex Transm Dis 39:21-4. 2012
    ..1 vs. 6.0 days) and cessation of herpes simplex virus shedding (HR = 1.88, P = 0.008; mean, 3.0 vs. 5.0 days) compared with placebo, similar to results of studies in high-income countries (ClinicalTrials.gov registration NCT00808405)...
  6. pmc Antiretroviral prophylaxis for HIV prevention in heterosexual men and women
    Jared M Baeten
    Department of Global Health, University of Washington, Seattle, WA 98104, USA
    N Engl J Med 367:399-410. 2012
    ..Antiretroviral preexposure prophylaxis is a promising approach for preventing human immunodeficiency virus type 1 (HIV-1) infection in heterosexual populations...
  7. doi request reprint A prospective study of contraceptive use among African women in HIV-1 serodiscordant partnerships
    Renee Heffron
    Department of Epidemiology, University of Washington, Seattle, WA 98104, USA
    Sex Transm Dis 37:621-8. 2010
    ..Few studies have explored contraceptive use in HIV-1 serodiscordant couples, a population at high risk for HIV-1 transmission...
  8. pmc Male circumcision and risk of male-to-female HIV-1 transmission: a multinational prospective study in African HIV-1-serodiscordant couples
    Jared M Baeten
    University of Washington, WA, USA
    AIDS 24:737-44. 2010
    ....
  9. pmc Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study
    Jairam R Lingappa
    Department of Global Health, University of Washington, Seattle, Washington, United States of America
    PLoS ONE 4:e5272. 2009
    ..We describe the baseline characteristics of this cohort...